Drug Trial Radar · NCT02770729
Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.
Last checked: Nov 20, 2026Latest source record: Aug 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3,640
Actual
Start
Jan 2017
Primary completion
Feb 2018
Study completion May 7, 2018
Sponsor
- Lead sponsor
- University of Campinas, BrazilAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 110 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
There has thus far been only one randomized and masked clinical trial in the world to evaluate the efficacy of the intraoperative intracameral injection of antibiotics with the objective of preventing endophthalmitis following cataract surgery. The ESCRS study from 2007 confirmed that the intracameral use of cefuroxime reduced the incidence of endophthalmitis approximately fivefold. Unlike in Europe, where this drug came to be widely used after the 2007 results, cefuroxime is not commercially available in Brazil. Many studies around the world have substituted cefuroxime with moxifloxacin, which is a drug that is easily found around the world in eye drop form. It is widely used in postoperative regimens in cases of ophthalmologic surgeries, and it is free of preservatives that are toxic to intraocular structures (corneal endothelial cells). Three studies (all respective) found that the intracameral use of moxifloxacin is safe and effective for preventing endophthalmitis following cataract surgery; however, no controlled, randomized, and masked clinical trials have been performed with this objective. If this trial confirms its hypothesis (a reduction in the incidence of endophthalmitis following cataract surgery) and if minimal side effects are reported, moxifloxacin may be an option for routine intracameral use during cataract surgery, thus reducing cases of endophthalmitis and consequent cases of blindness.
Conditions
- Endophthalmitis
Interventions
MoxifloxacinDrug
Intracameral injection of moxifloxacin at conclusion of cataract surgery
No injection of moxifloxacinDrug
No intracameral injection of moxifloxacin at conclusion of cataract surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endophthalmitis incidenceTime frame: 45 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mathias Violante Mélega
Campinas, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.